KORU Medical CEO Buys 1,191 Shares at $3.92, Signaling Confidence Amid Volatility

Insider Buying at KORU Signals Confidence Amid Volatility

A recent director‑dealing filing shows CEO Tharby Linda M purchasing 1,191 shares of KORU Medical Systems at $3.92 on May 15, 2026. The trade is part of a cluster of transactions over the past month where the executive’s holdings rose from 619,431 to 620,622 shares. The purchase price—slightly below the prevailing market price of $4.00—suggests the CEO is taking advantage of a marginal dip in the stock’s valuation.

What the Buy Means for Investors

KORU’s share price has been on an upward trajectory, rising 3.9 % weekly but down 6.1 % monthly. The CEO’s buying activity comes at a time when the company’s earnings outlook remains uncertain, given a negative price‑earnings ratio of –76.2 and a modest market cap of $179 million. Insider purchases in this context are often interpreted as a sign of management’s confidence in the company’s long‑term prospects, especially when the trades are sizable relative to the float. The sentiment score of +42 and a buzz of 73 % in social‑media channels indicate that the market is reacting positively, albeit with moderate intensity.

Implications for KORU’s Future

The incremental ownership by the CEO, coupled with similar buying by the COO and CFO, suggests that senior management is positioning themselves to benefit from the company’s projected growth in the subcutaneous infusion device market. If KORU successfully expands its product pipeline or secures new payer contracts, the stock could rebound from its current 52‑week low of $2.63 to the high of $6.61 seen last year. However, the company’s negative earnings multiple and the recent decline in its stock price warrant caution; investors should monitor upcoming quarterly results and any regulatory developments that could impact device approvals.

A Profile of CEO Tharby Linda M

Tharby has a consistent buying pattern: in March 2026 she added 15,968 shares and sold 5,756, while in April 2025 she sold a large block of 23,587 shares at $2.20. The most recent purchase reflects a trend of acquiring shares at or below market price, often following a dip. Her transaction history shows a willingness to sell when prices are higher (e.g., April 2025) and to buy when they fall, indicating a long‑term investment thesis rather than opportunistic trading. This disciplined approach, combined with the recent buy at $3.92, aligns with a belief that KORU’s valuation will eventually recover.

Bottom Line for Traders and Portfolio Managers

For those tracking the health‑care equipment sector, KORU’s insider buying—especially by the CEO—offers a subtle bullish signal in an otherwise volatile environment. The stock’s modest liquidity and the company’s negative valuation metrics mean that a single trade may not move the market, but cumulative insider activity could presage a shift in investor sentiment. Investors should weigh the CEO’s confidence against the backdrop of KORU’s financial fundamentals and upcoming product milestones before allocating capital.